Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas.

Ueng SH, Chen SC, Chang YS, Hsueh S, Lin YC, Chien HP, Lo YF, Shen SC, Hsueh C.

Int J Clin Exp Pathol. 2012;5(8):806-13. Epub 2012 Oct 1.

2.

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Tang D, Xu S, Zhang Q, Zhao W.

Med Oncol. 2012 Jun;29(2):526-33. doi: 10.1007/s12032-011-9948-2. Epub 2011 Apr 26.

PMID:
21519872
3.

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.

Hum Pathol. 2012 Jan;43(1):23-30. doi: 10.1016/j.humpath.2011.04.011. Epub 2011 Jul 20.

PMID:
21777944
4.

mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.

Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A, Duffy MJ.

Breast. 2012 Apr;21(2):178-82. doi: 10.1016/j.breast.2011.09.008. Epub 2011 Sep 29.

PMID:
21963359
5.

Novel prognostic markers for patients with triple-negative breast cancer.

Zhou L, Li K, Luo Y, Tian L, Wang M, Li C, Huang Q.

Hum Pathol. 2013 Oct;44(10):2180-7. doi: 10.1016/j.humpath.2013.03.021. Epub 2013 Jul 8.

PMID:
23845466
6.

High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer.

Zhao H, Yang M, Zhao J, Wang J, Zhang Y, Zhang Q.

Med Oncol. 2013 Mar;30(1):475. doi: 10.1007/s12032-013-0475-1. Epub 2013 Feb 1.

PMID:
23371253
7.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

8.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
9.
10.

Clinicopathological features of triple-negative breast cancer in Taiwanese women.

Yao-Lung K, Dar-Ren C, Tsai-Wang C.

Int J Clin Oncol. 2011 Oct;16(5):500-5. doi: 10.1007/s10147-011-0211-9. Epub 2011 Apr 1.

PMID:
21455625
11.

[Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].

Ma JG, Wang NJ, Yu WJ.

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Oct;31(10):1729-32. Chinese.

12.

Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.

Koo JS, Jung W.

Pathobiology. 2010;77(6):289-300. doi: 10.1159/000320936. Epub 2011 Jan 24.

PMID:
21266827
13.

Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.

Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC.

Breast Cancer Res Treat. 2011 Feb;126(1):93-9. doi: 10.1007/s10549-010-1315-z. Epub 2010 Dec 24.

PMID:
21184268
14.

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, Pruneri G, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M.

Clin Breast Cancer. 2013 Feb;13(1):31-9. doi: 10.1016/j.clbc.2012.09.002. Epub 2012 Oct 24.

PMID:
23098574
15.

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.

Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2009 Jul;116(2):317-28. doi: 10.1007/s10549-008-0206-z. Epub 2008 Oct 7.

PMID:
18839307
16.

Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.

Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.

Hum Pathol. 2008 Dec;39(12):1809-15. doi: 10.1016/j.humpath.2008.05.010. Epub 2008 Aug 19.

PMID:
18715613
17.

Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.

Choi JE, Kang SH, Lee SJ, Bae YK.

Ann Surg Oncol. 2015 Jan;22(1):82-9. doi: 10.1245/s10434-014-3984-z. Epub 2014 Aug 22.

PMID:
25145503
18.

c-erbB-2 and the "triple-state" in early breast carcinomas.

Sivridis E, Stamos C, Fiska A, Nikolettos N, Koukourakis MI, Giatromanolaki A.

Med Oncol. 2010 Sep;27(3):578-84. doi: 10.1007/s12032-009-9252-6. Epub 2009 Jun 23.

PMID:
19548127
19.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

20.

Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.

Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ.

Am J Surg Pathol. 2007 Jan;31(1):129-40.

PMID:
17197929

Supplemental Content

Support Center